EPIDERMOLYSIS BULLOSA AND TAPELESS

Epidermolysis bullosa, or ”EB”, is a group of disorders involving degrees of severity of blister formation with resultant scarring, deformities, secondary infections, skin cancers, eating abnormalities and even death.  The complications depend on the success of treatment, prevention of episodes of occurrence and the type of EB involved. With E.B., secondary wound dressings have as much impact as with any wound disorder.  It can make a positive or negative impact on the comfort of the patient, cost management, prevention of complications and ease of wound management.

The goal of treatment is to prevent the formation of blisters and any subsequent complications.  The use of adhesives is forbidden and the use of clothing and secondary wound dressings that are simple to get on and off are encouraged.  Tapeless products are very beneficial in the management of this disorder and Tapeless has begun to work with EB patients through a relationship with the DebRA Foundation, a remarkable organization dedicated to this inherited disorder. (www.debra.org.)  Since this disorder generally begins at birth or soon thereafter, Tapeless, with the ability to manufacture its products in any size, has produced smaller versions of those products that have the most applicability to the patient needs with this disorder.  Early feedback from the parents of these trial cases is very positive, with dressing changes less painful, better tolerated by the child, quicker and easier to apply/remove and more cost effective.  The more frequent and tolerable the dressing changes, the better the wound management.  Features, such as no adhesives, anatomic shape, breathability, washability/reusability, no constriction, absence of bulk and Medicare Part B reimbursement, allow these products to provide an ideal clinical dressing alternative with the ability to minimize complication occurrence and improve the quality of life for patient and family

As Tapeless continues to work with organizations like The DebRA Foundation and pediatric hospitals demonstrating an interest in treating this disorder, we look forward to contributing further in the overall management of EB. 

www.tapelessmedical.com